BlackRock Health Sciences plans up to 5% tender offer
The scheduled offer would be priced at 98% of NAV, with prorated purchases if shareholders tender more than 5% of shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock Health Sciences Term Trust (BMEZ) has a Board-authorized tender offer for up to 5% of its outstanding common shares. Its average daily discount to NAV was 11.05% for the Measurement Period ended September 30, 2026, exceeding the program’s greater-than-10.00% trigger. The anticipated commencement date is October 16, 2026; the offer is scheduled to expire November 18, 2026, at 5:00 p.m. Eastern Time, unless extended.
The offer price is 98% of NAV per share, based on NAV calculated on the next day it is calculated after expiration (or after an extended expiration, if applicable). If more than 5% of shares are tendered, purchases will be made pro rata, and the Fund says there is no assurance it will purchase all shares a shareholder tenders. Payments for accepted shares are expected within approximately five business days after expiration.
Key Figures
Key Terms
net asset value financial
Measurement Period financial
pro rata basis financial
Trigger Event regulatory
Letter of Transmittal regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does the BMEZ tender offer begin and end?
AI-generated analysis. How Rhea-AI works. Not financial advice.
As filed with the Securities and Exchange Commission on October 1, 2026
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
TENDER OFFER STATEMENT
Under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
BlackRock Health Sciences Term Trust
(Name of Subject Company (Issuer))
BlackRock Health Sciences Term Trust
(Names of Filing Person(s) (Issuer))
Common Shares of Beneficial Interest, Par Value $0.001 per share
(Title of Class of Securities)
09260E105
(CUSIP Number of Class of Securities)
John M. Perlowski
BlackRock Health Sciences Term Trust
50 Hudson Yards
New York, New York 10001
1-800-441-7762
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person(s))
Copies to:
| Margery K. Neale, Esq. | ||
| Elliot J. Gluck, Esq. | Janey Ahn, Esq. | |
| Willkie Farr & Gallagher LLP | BlackRock Advisors, LLC | |
| 787 Seventh Avenue | 50 Hudson Yards | |
| New York, New York 10019 | New York, New York 10001 |
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which this statement relates:
| ☐ | third-party tender offer subject to Rule 14d-1 |
| ☒ | issuer tender offer subject to Rule 13e-4 |
| ☐ | going-private transaction subject to Rule 13e-3 |
| ☐ | amendment to Schedule 13D under Rule 13d-2 |
Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐
Contact:
1-800-882-0052
Certain BlackRock Closed-End Funds Provide Updates on their Discount Management Programs
New York, October 1, 2026 – The BlackRock closed-end funds (the “Funds”) listed below announced today the results of the Measurement Period (as defined below) under their previously announced discount management programs (the “Programs”).
Under the Programs, if a Fund’s common shares trade at an average daily discount to net asset value (“NAV”) of greater than 10.00% during the 9-month measurement period (the “Measurement Period”), the Fund intends to offer to repurchase, as soon as practicable following the Measurement Period end date, a minimum of 5% of its outstanding common shares at a price equal to 98% of the Fund’s NAV, as determined on the trading day after the tender offer expires.
The average daily premium/(discount) to NAV for the Funds during the Measurement Period are summarized below.
Measurement Period Results for the Funds in the Program
| Fund Name |
Ticker | Average Daily Premium/(Discount) for the Measurement Period ended September 30, 2026 | ||
| BlackRock Capital Allocation Term Trust |
BCAT | 3.30% | ||
| BlackRock ESG Capital Allocation Term Trust |
ECAT | (2.74)% | ||
| BlackRock Science and Technology Term Trust |
BSTZ | (9.45)% | ||
| BlackRock Health Sciences Term Trust |
BMEZ | (11.05)% | ||
| BlackRock Enhanced Global Dividend Trust |
BOE | (9.05)% | ||
| BlackRock Energy and Resources Trust |
BGR | (8.99)% | ||
| BlackRock Enhanced International Dividend Trust |
BGY | (9.22)% | ||
| BlackRock Enhanced Large Cap Core Fund, Inc. |
CII | 1.10% | ||
| BlackRock Enhanced Equity Dividend Trust |
BDJ | (6.42)% | ||
| BlackRock Science and Technology Trust |
BST | (6.10)% | ||
| BlackRock Health Sciences Trust |
BME | (3.78)% | ||
| BlackRock Resources & Commodities Strategy Trust |
BCX | (6.84)% | ||
| BlackRock Utilities, Infrastructure, & Power Opportunities Trust |
BUI | 1.39% | ||
| BlackRock MuniHoldings Fund, Inc. |
MHD | (8.17)% | ||
| BlackRock MuniYield New York Quality Fund, Inc. |
MYN | (8.00)% | ||
| BlackRock MuniHoldings California Quality Fund, Inc. |
MUC | (7.61)% | ||
| BlackRock MuniYield Quality Fund, Inc. |
MQY | (7.41)% | ||
| BlackRock MuniAssets Fund, Inc. |
MUA | (4.80)% | ||
| BlackRock MuniYield Quality Fund III, Inc. |
MYI | (7.42)% |
1
Based on BMEZ’s average daily discount during the Measurement Period, the Fund will conduct a tender offer for up to 5% of the Fund’s outstanding common shares at a price equal to 98% of the Fund’s NAV per share as determined as of the close of the regular trading session of the New York Stock Exchange (“NYSE”) on the next day the NAV is calculated after the expiration date of the tender offer or, if the offer is extended, on the next day the NAV is calculated after the day to which the offer is extended. As a result of the occurrence of a Trigger Event during the Measurement Period, BMEZ’s Board of Trustees has authorized the Fund’s tender offer with the anticipated commencement and expiration dates outlined below.
| Tender Offer Commencement Date | Friday, October 16, 2026 | |
| Tender Offer Expiration Date and Time | Wednesday, November 18, 2026, at 5:00 p.m. Eastern Time, unless otherwise extended | |
If more than 5% of BMEZ’s outstanding common shares are tendered, the Fund will purchase its shares from tendering shareholders on a pro rata basis at a price equal to 98% of the Fund’s NAV per share as determined as of the close of the regular trading session of the NYSE on the next day the NAV is calculated after the expiration date of the tender offer (or, if the offer is extended, on the next day the NAV is calculated after the day to which the offer is extended). Accordingly, there is no assurance that BMEZ will purchase all of a shareholder’s common shares tendered in the tender offer. Payments for shares tendered and accepted for repurchase are expected to be made within approximately five business days after the expiration date.
The terms and conditions of BMEZ’s tender offer will be set forth in an Offer to Purchase, a related Letter of Transmittal, and related documents, which will be distributed to BMEZ’s common shareholders. As soon as its tender offer commences, BMEZ will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (the “SEC”), which will include an Offer to Purchase and related Letter of Transmittal.
Tender offers are not required for the remaining Funds under the Programs and therefore those Funds will not be conducting tender offers.
The Programs are part of each Fund’s ongoing effort to manage their discount to NAV, enhance long-term shareholder value and provide liquidity to the market for their common shareholders. There can be no assurances as to the effect, if any, that the Program will have on the market for each Fund’s shares or the discount at which each Fund’s shares may trade relative to their NAV.
2
IMPORTANT NOTICE
This press release is for informational purposes only and is not a recommendation, an offer to purchase or a solicitation of an offer to sell any securities of the Funds and the above statements are not intended to constitute an offer to participate in any tender offer. Any offer to purchase Fund common shares will be made pursuant to an offer on Schedule TO. COMMON SHAREHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS, INCLUDING THE OFFER TO PURCHASE AND ANY SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE TENDER OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN THEY ARE FILED AND BECOME AVAILABLE, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF COMMON SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. Common shareholders may obtain a free copy of any of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the applicable Fund.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate
Availability of Fund Updates
BlackRock will update performance and certain other data for the Funds on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Funds. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Funds and does not, and is not intended to, incorporate BlackRock’s website in this release.
Forward-Looking Statements
This press release, and other statements that BlackRock or a Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to a Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.
BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.
3
With respect to the Funds, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Funds or in a Fund’s net asset value; (2) the relative and absolute investment performance of a Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to a Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.
Annual and Semi-Annual Reports and other regulatory filings of the Funds with the SEC are accessible on the SEC’s website at www.sec.gov and on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Funds. The information contained on BlackRock’s website is not a part of this press release.
##
4